Summary
We report a novel cause of partial lipodystrophy associated with early B cell factor 2 (EBF2) nonsense variant (EBF2 8:26033143 C>A, c.493G>T, p.E165X) in a patient with an atypical form of partial lipodystrophy. The patient presented with progressive adipose tissue loss and metabolic deterioration at pre-pubertal age. In vitro and in vivo disease modeling demonstrates that the EBF2 variant impairs adipogenesis, causing excess accumulation of undifferentiated CD34+ cells, extracellular matrix proteins, and inflammatory myeloid cells in subcutaneous adipose tissues. Thus, this EBF2 p.E165X variant disrupts adipose tissue structure and function, leading to the development of partial lipodystrophy syndrome.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Clinical phenotyping was made possible by NIH grant 5R03DK074488 (Oral EA) and by Lipodystrophy Research Fund (Oral EA) established at the University of Michigan Medical School through philanthropic support (by Sopha Family, Baker family, Rosenblum family and White Point Foundation of Turkey). Infrastructure support has been enabled by NIH grants 2P30DK089503, 5P30DK020572, and UL1TR002240, as well as support from Caswell Diabetes Institute of Michigan Medicine. Sequencing and analysis were provided by the Broad Institute of MIT and Harvard Center for Mendelian Genomics (Broad CMG) and were funded by the NIH grant K23DK114551, National Human Genome Research Institute grants UM1HG008900 (with additional support from the National Eye Institute, and the National Heart, Lung and Blood Institute) and R01HG009141, and in part by Chan Zuckerberg Initiative grant DAF2019-199278 (https://doi.org/10.37921/236582yuakxy), an advised fund of Silicon Valley Community Foundation (funder DOI 10.13039/100014989).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Written consent was obtained from the patient, and all procedures involving the patient were approved by the Institutional Review Boards of Michigan Medicine and Massachusetts General Brigham and complied with the Declaration of Helsinki.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
